Who Owns Alembic Pharma?
Ownership snapshot for Mar 2026
Unlock Full Ownership Intelligence
Go beyond a snapshot — track 12 quarters of shareholding trends, insider trading activity, and AI-powered signals.
- 12 quarters of shareholding trend data
- Insider trading & bulk deal analysis
- AI-powered shareholding insights & signals
Billed annually
Understanding Shareholding Categories
Promoter (Non-Pledged): Founders & holding companies. High holding (>50%) shows alignment with shareholders.
Promoter (Pledged): Shares used as loan collateral. Forced selling risk if loans default.
DII: Mutual funds, insurance & pension funds. Rising DII stake signals domestic confidence.
FII: Foreign portfolio investors & hedge funds. High FII stake shows global interest.
Government: Central/state govt & PSU holdings.
Public & Others: Retail investors, HNIs, NRIs & corporates.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar 2026
Related Stocks
Viyash Scientific (VIYASH)
Turned profitable with net income of ₹32.3 Cr in FY2025.
Natco Pharma (NATCOPHARM)
Revenue grew 15.9% to ₹4,784 Cr in FY2025.
Neuland (NEULANDLAB)
Revenue of ₹1,497 Cr in FY2025.
Wockhardt (WOCKPHARMA)
Reported a net loss of ₹57.0 Cr in FY2025.
Strides Arcolab (STAR)
Turned profitable with net income of ₹3,598 Cr in FY2025.
Jubilant Pharmova (JUBLPHARMA)
Revenue of ₹7,291 Cr in FY2025.